Pirfenidone Initiates a New Era in the Treatment of Idiopathic Pulmonary Fibrosis

被引：41

作者：

Selvaggio, Anna S. ^{[1
]}

Noble, Paul W. ^{[1
]}

机构：

[1] Cedars Sinai Med Ctr, Dept Med, Los Angeles, CA 90048 USA

来源：

ANNUAL REVIEW OF MEDICINE, VOL 67 | 2016年 / 67卷

关键词：

pirfenidone; idiopathic pulmonary fibrosis; interstitial lung disease; Esbriet (R); NECROSIS-FACTOR-ALPHA; OPEN-LABEL; PHASE-3; TRIAL; DOUBLE-BLIND; SURVIVAL; ACETYLCYSTEINE; PROLIFERATION; ACTIVATION; CAPACITY; RECEPTOR;

D O I：

10.1146/annurev-med-120214-013614

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, and fatal disease that has long eluded therapy. Prognosis remains very poor, and currently lung transplantation offers the only hope of survival. Recently, great strides have been made in the development of pharmaceutical therapy to treat IPF. Pirfenidone, an oral antifibrotic agent, has been shown to slow progression of the disease and improve progression-free survival, offering new hope for patients suffering from IPF.

引用

页码：487 / 495

页数：9

共 46 条

[1]

Amer Thoracic Soc, 2000, AM J RESP CRIT CARE, V161, P646

[2]

[Anonymous], COCHRANE DATABASE SY

[3] Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis [J].

Azuma, A ;

Nukiwa, T ;

Tsuboi, E ;

Suga, M ;

Abe, S ;

Nakata, K ;

Taguchi, Y ;

Nagai, S ;

Itoh, H ;

Ohi, M ;

Sato, A ;

Kudoh, S ;

Raghu, G .

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2005, 171 (09) :1040-1047

[4] Management of patients with idiopathic pulmonary fibrosis in clinical practice: the INSIGHTS-IPF registry [J].

Behr, Juergen ;

Kreuter, Michael ;

Hoeper, Marius M. ;

Wirtz, Hubert ;

Klotsche, Jens ;

Koschel, Dirk ;

Andreas, Stefan ;

Claussen, Martin ;

Grohe, Christian ;

Wilkens, Henrike ;

Randerath, Winfried ;

Skowasch, Dirk ;

Meyer, F. Joachim ;

Kirschner, Joachim ;

Glaeser, Sven ;

Herth, Felix J. F. ;

Welte, Tobias ;

Huber, Rudolf Maria ;

Neurohr, Claus ;

Schwaiblmair, Martin ;

Kohlhaeufl, Martin ;

Hoeffken, Gert ;

Held, Matthias ;

Koch, Andrea ;

Bahmer, Thomas ;

Pittrow, David .

EUROPEAN RESPIRATORY JOURNAL, 2015, 46 (01) :186-196

[5] Open-label study of pirfenidone in patients with progressive forms of multiple sclerosis [J].

Bowen, JD ;

Maravilla, K ;

Margolin, SB .

MULTIPLE SCLEROSIS JOURNAL, 2003, 9 (03) :280-283

[6] Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis [J].

Collard, HR ;

King, TE ;

Bartelson, BB ;

Vourlekis, JS ;

Schwarz, MI ;

Brown, KK .

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2003, 168 (05) :538-542

[7] Effect of pirfenidone on proliferation, TGF-β-induced myofibroblast differentiation and fibrogenic activity of primary human lung fibroblasts [J].

Conte, Enrico ;

Gili, Elisa ;

Fagone, Evelina ;

Fruciano, Mary ;

Iemmolo, Maria ;

Vancheri, Carlo .

EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2014, 58 :13-19

[8]

Costabel U, 2011, EUR RESP J S55, V38, p174s

[9]

Costabel U, 2014, SARCOIDOSIS VASC DIF, V31, P198

[10] Long-term clinical and real-world experience with pirfenidone in the treatment of idiopathic pulmonary fibrosis [J].

Cottin, Vincent ;

Maher, Toby .

EUROPEAN RESPIRATORY REVIEW, 2015, 24 (135) :58-64

← 1 2 3 4 5 →